Lu177 ‐PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution

ConclusionInitial experience at our site supports the use of LuPSMA as an emerging safe and effective treatment for mCRPC. Since introducing LuPSMA therapy at our institution, 44.9% of patients have experienced a decline in PSA level  ≥ 50% with low or minimal toxicity. This is an important finding as these patients had previously exhausted all available treatment options. Overall, we have found patients and their primary care doctors have eagerly accepted LuPSMA as another line of defence against mCRPC.
Source: Journal of Medical Imaging and Radiation Oncology - Category: Radiology Authors: Tags: Radiation Oncology —Original Article Source Type: research

Related Links:

This article reviews the major pathways by which adrenal steroids are converted to the potent male sex hormones, testosterone (T) and 5α-dihydrotestosterone (5α-DHT) and the discrete enzyme isoforms involved in castration resistant prostate cancer. Previous studies have mainly utilized radiotracers to investigate these pathways but have not used prevailing concentrations of precursors found in castrate male human serum. In addition, the full power of stable-isotope dilution liquid chromatography tandem mass spectrometry has not been applied routinely. Furthermore, it is clear that adaptive responses occur in th...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
Publication date: Available online 13 October 2019Source: European UrologyAuthor(s): Bruce Montgomery, Stephen Plymate
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 12 October 2019Source: Journal of Molecular LiquidsAuthor(s): Nazanin Mokhtari, Somayeh Taymouri, Mina Mirian, Mohammad DinariAbstractIn the present study, a novel polyimine-based covalent triazine framework (PI-CTF) was introduced as a promising biocompatible carrier for sorafenib (SFN) delivery. High specific surface area and porosity allowed us to achieve drug loading and encapsulation efficiency as high as 83% and 98%, respectively. The in vitro drug release study of SFN-loaded PI-CTF showed a sustained and pH-dependent release behavior in which acidic pH accelerated drug release comp...
Source: Journal of Molecular Liquids - Category: Molecular Biology Source Type: research
Conclusion: Refraining from voiding prior to F-18-fluciclovine injection results in significantly lower urinary bladder radioactivity compared to purposeful voiding pre-injection. We have modified our practice accordingly, particularly as moderate and intense bladder activity may mask/mimic local prostate cancer recurrence. Mechanisms underlying this phenomenon should be further investigated. PMID: 31604898 [PubMed - as supplied by publisher]
Source: Journal of Nuclear Medicine Technology - Category: Nuclear Medicine Tags: J Nucl Med Technol Source Type: research
Conclusion: The study shows that the use of 213Bi-PSMA/DOTATOC for the therapy of CRPC and NET, respectively, has been convenient, safe and straightforward. The external radiation doses to the occupational workers involved in different procedures were far below the dose limits prescribed by the Regulatory Authority (20mSv/yr). The dose rates from the treated patients showed no detrimental effect on public and environment. PMID: 31604889 [PubMed - as supplied by publisher]
Source: Journal of Nuclear Medicine Technology - Category: Nuclear Medicine Tags: J Nucl Med Technol Source Type: research
(Natural News) Prostate cancer is among the leading cancers in men in the U.S., second only to skin cancer. The American Cancer Society estimates around 174,650 new cases of – and 31,620 deaths from – prostate cancer each year, in its latest report. Fortunately, new evidence suggests that eating certain foods could play a role in starving – or even preventing – cancer....
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
Authors: Bozkurt S, Park JI, Kan KM, Ferrari M, Rubin DL, Brooks JD, Hernandez-Boussard T Abstract Digital rectal examination (DRE) is considered a quality metric for prostate cancer care. However, much of the DRE related rich information is documented as free-text in clinical narratives. Therefore, we aimed to develop a natural language processing (NLP) pipeline for automatic documentation of DRE in clinical notes using a domain-specific dictionary created by clinical experts and an extended version of the same dictionary learned by clinical notes using distributional semantics algorithms. The proposed pipeline wa...
Source: AMIA Annual Symposium Proceedings - Category: Bioinformatics Tags: AMIA Annu Symp Proc Source Type: research
CONCLUSION: MRI/TRUS TG in combination with SB had significantly higher detection rates than SB in the RB group only. Differences in detection rates between examiners were dependent on the level of previous experience with TRUS guided biopsy. PMID: 31602045 [PubMed - as supplied by publisher]
Source: Biomedical Papers of the Medical Faculty of the Univ Palacky Olomouc Czech Repub - Category: Biomedical Science Tags: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Source Type: research
Men who conceive children using assisted reproduction techniques (ART) like in vitro fertilization (IVF) are more likely to develop prostate cancer and may benefit from screening, a study suggests.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
This study aims to analyze the prognostic importance of serum PSA response in patients who received radioligand therapy (RLT) with Lu-177 Prostate-specific membrane antigen (PSMA) for their castration-resistant prostate cancer. METHODS: Thirty consecutive patients who received Lu-177 PSMA treatment for their castration-resistant prostate carcinoma were included. All the patients had undergone Ga-68 PSMA PET/CT scanning before Lu-177 PSMA therapy, which revealed multiple metastases. Patients were treated with a fixed dose (180 mCi) of Lu-177 PSMA at six to eight weeks intervals. Prostate specific antigen (PSA) response ...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research
More News: Australia Health | Cancer | Cancer & Oncology | Primary Care | Prostate Cancer | Radiology | Toxicology